Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis.

Abstract

Thirty-six patients with subarachnoid and intraventricular cysticercosis were randomly assigned to receive albendazole at 15 or 30 mg/kg/day plus dexamethasone for 8 days. Results favored a higher dose, with larger cyst reduction on MRI at 90 and 180 days and higher albendazole sulfoxide levels in plasma. An albendazole course at 30 mg/kg/day combined with corticosteroids is safe and more effective than the usual dose. A single treatment was insufficient in intraventricular and giant cysts.

• Authors: F Göngora-Rivera, J L Soto-Hernández, D González Esquivel, H J Cook, C Márquez-Caraveo, R Hernández Dávila, J Santos-Zambrano
• Journal: Neurology (Neurology) Vol. 66 Issue 3 Pg. 436-8 (Feb 14 2006) ISSN: 1526-632X [Electronic] United States
• PMID: 16382035 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• Anticestodal Agents
• Dexamethasone
• Albendazole

Topics

• Adult
• Albendazole (administration & dosage, adverse effects, therapeutic use)
• Anticestodal Agents (administration & dosage, adverse effects, therapeutic use)
• Cerebral Ventricles (parasitology)
• Dexamethasone (administration & dosage, therapeutic use)
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Drug Therapy, Combination
• Female
• Headache (chemically induced)
• Humans
• Male
• Middle Aged
• Neurocysticercosis (drug therapy)
• Subarachnoid Space (parasitology)
• Treatment Outcome